Arrowhead Pharmaceuticals Inc

ARWR remains in a Stage 2 advancing regime with clear higher highs and higher lows supported by rising EMAs and volume expansion—preserving a bullish medium-term outlook. However, the recent Bullish Exhaustion candle, price extension above key EMAs, and RSI nearing overbought levels signal short-term fatigue. We will Stalk for a corrective pullback into the 9/21 EMA zone for a potential entry.

• ↑Redempla FDA-approved for FCS generates 400+ prescriptions post-launch
• ↑FY25 revenue surged to $829 M, cash balance $919 M supports R&D
• ↓Q2 operating expenses climbed to $731 M, accelerating cash burn